CliffBio
biologic

Conexxence

denosumab-bnht

Loss of exclusivity—loss of exclusivity
CompanyFresenius Kabi →See this company's full patent-cliff portfolio

Drug detail

Brand nameConexxence
Active ingredientdenosumab-bnht
Strength60MG/ML
Dosage formInjection
RouteSubcutaneous
ModalityBiologic
FDA approvalMarch 2025
Marketing statusRx

More from Fresenius Kabi

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.